Regulatory CD4+ CD25+ Foxp3+ T cells expand during experimental Plasmodium infection but do not prevent cerebral

Ana Margarida Vigário1, Olivier Gorgette, Hélène C Dujardin

  • 1Instituto Gulbenkian de Ciência, 2781-901 Oeiras, Portugal.

Insights

Pathogenic CD8+ T cells drive experimental cerebral malaria (CM). Despite increased splenic regulatory T cells (Tregs) with enhanced in vitro function during Plasmodium berghei ANKA infection, these Tregs do not migrate to the brain or protect against CM.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Neuroscience

Background:

  • Pathogenic CD8+ T cells contribute to experimental cerebral malaria (CM) pathogenesis.
  • CD4+ CD25+ regulatory T cells (Tregs) are crucial for controlling immune responses.

Purpose of the Study:

  • To investigate the role of CD4+ CD25+ Treg cells in controlling pathogenic effector T cells during experimental cerebral malaria (CM).
  • To determine if Treg cells are involved in the neuropathology of CM.

Main Methods:

  • Flow cytometry to analyze T cell populations (CD4+, CD8+, CD25+, Foxp3+, CD69+).
  • In vitro assays to assess Treg suppressive function.
  • Experimental cerebral malaria (CM) induction in mice infected with Plasmodium berghei ANKA (PbA).
  • Treatment with anti-CD25 antibodies to deplete Tregs.

Main Results:

  • The number of splenic CD4+ CD25high T cells expressing Foxp3 increased during PbA infection.
  • These splenic Tregs exhibited enhanced regulatory activity in vitro.
  • Tregs did not migrate to the brain during the onset of neurological symptoms.
  • CM was not exacerbated in mice depleted of Tregs prior to PbA infection.

Conclusions:

  • Plasmodium berghei ANKA infection increases the number and in vitro suppressive function of splenic CD4+ CD25high Treg cells.
  • Despite their enhanced in vitro function, these Tregs do not appear to be involved in the in vivo protection against experimental cerebral malaria (CM).
  • The neuropathology of CM is not primarily mediated by inefficient Treg control of pathogenic effector T cells.